An Open-label Phase I Study of Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 03 Mar 2010 Actual patient number (12) added as reported by ClinicalTrials.gov.
- 03 Mar 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.